The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel

British Journal of Cancer

Volumn 84, Issue 8, 2001, Pages 1126-1134

  Jagdev, S P ^a   Coleman, R E ^a   Shipman, C M ^a   Rostami H , A ^a   Croucher, P I ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Apoptosis; Bisphosphonate; Breast cancer; Paclitaxel

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GERANYLGERANIOL; MEVALONIC ACID; PACLITAXEL; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA NICK TRANSLATION; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL COUNT; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; IMIDAZOLES; MEVALONIC ACID; PACLITAXEL; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0035917560     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1727     Document Type: Article

References (33)

1. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J and Lichtenstein A (1998) In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukaemia 12: 220-229
2. Berenbaum M (1989) What is synergy? Pharmacol Rev 41: 93-141
3. Berenson J, Lichtenstein A, Porter L, Dimopoulos M, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone J, Reitsma D, Heffernan M, Seaman J and Knight R (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New Engl J Med 334: 488-493
4. Berenson JR, Ravera C, Ma P, Deckert F, Sasaki Y, Saeki T, Takashima S, LoRusso P, Goodin S, Seaman J, Schran H and Zhou H (2000) Population Pharmacokinetics (PK) of Zometa. Proc ASCO
5. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas, PD and Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57: 3890-3894
6. Coxon FP, Benford HL, Russell RG and Rogers MJ (1998) Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 54: 631-638
7. Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL and Bataille R (1999) Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14: 2048-56
8. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodmate treatment. New Engl J Med 339: 357-363
9. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA and Reska AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96: 133-8
10. Frith JC, Monkkonen J, Blackburn GM, Russell RG and Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analogue, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358-67
11. Fromigue O and Body J (2000) Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15: 2211-2221
12. Gessner, P (1988) A straightforward method for the study of drug interactions: an isobolographic primer. J Am Coll Toxicol 7: 987-1012
13. Gorezyca W, Myron R, Melamed and Darzynkiewicz Z (1993) Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: Detection of DNA strand breaks by flow cytometry using the in situ nick translation assay. Toxicol Lett 67: 249-258
14. Greco WR, Bravo G and Parsons J (1995) The search for synergy: A critical review from a response surface perspective. Pharmacol Rev 47: 331-385
15. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J and Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. New Engl J Med 335: 1785-1791
16. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR and Boyce BF (1995) Bisphosphonates promote apotosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487
17. Kanis JA, Powles T, Paterson AH, McCloskey EV and Ashley S (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19: 663-667
18. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M and Clarke R (1994) Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobolograrn, drug accumulation and M 170, 000 glycoprotein (gp170) binding studies. Cancer Res 54: 441-447
19. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G and Rogers MJ (1998) Nitrogen-containing bishosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589
20. Magnetto S, Boissier S, Delmas PD and Clezardin P (1999) Additive anti-tumour activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 83: 263-269
21. McCloskey EV, Maclennan CM, Drayson MT, Chapman C, Dunn J and Kanis JA (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 100: 317-325
22. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr and Kohn KW (1997) Characterization of the p53 tumour suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth- inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300
23. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J and Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65
24. Rogers M, Chilton K, Coxon F, Lawry J, Smith M, Suri S and Russell R (1996) Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 11: 1482-1491
25. Saarto T, Blomqvist C, Virkkunen P and Elomaa I (2000) Adjuvant clodronate does not reduce the frequency of skeletal metastases in node-positive breast cancer patients. J Clin Oncol 19: 10-19
26. Sato M, Grasser W, Endo N, Akins R, Simmons H and Thompson DD (1991) Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095-2105
27. Shipman CM, Rogers MJ, Apperley JF, Russell RG and Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 665-672
28. Shipman CM, Croucher PI, Russell RG, Helfrich MH and Rogers MJ (1998) The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58: 5294-5297
29. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M and Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17: 846-854
30. Van der Pluijm G, Vloedgraven H, Van Beek E, Van der Wee-Pals L, Lowik C and Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698-705
31. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J and O'Shaughnessy J (1994) Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase 1/11 trial of 96-hour infusion. J Clin Oncol 12: 1621-1629
32. Wyllie A, Kerr J and Currie A (1980) Cell death: The significance of apoptosis. Int Rev Cytol 68: 251-306
33. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M and Hiraga T (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88: (12 Suppl), 2979-2988